Carriers of CYP2C19*17 treated with clopidogrel had similar rate of the composite thrombotic outcome of cardiovascular death, MI, ST and stroke (CYP2C19*17–3.8% vs. CYP2C19*1–3.8%, p = 0.90) as well as similar major and minor bleeding rates when compared to carriers of the wild type treated with clopidogrel (CYP2C19*17–9.3% vs. CYP2C19*1–11.2%, p = 0.21). The gene discussed is CYP2C19; the disease is stroke disorder.